JP2024028453A5 - - Google Patents

Download PDF

Info

Publication number
JP2024028453A5
JP2024028453A5 JP2024002413A JP2024002413A JP2024028453A5 JP 2024028453 A5 JP2024028453 A5 JP 2024028453A5 JP 2024002413 A JP2024002413 A JP 2024002413A JP 2024002413 A JP2024002413 A JP 2024002413A JP 2024028453 A5 JP2024028453 A5 JP 2024028453A5
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
ceutically acceptable
rnai agent
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024002413A
Other languages
English (en)
Japanese (ja)
Other versions
JP7843302B2 (ja
JP2024028453A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/018232 external-priority patent/WO2019161213A1/en
Application filed filed Critical
Publication of JP2024028453A publication Critical patent/JP2024028453A/ja
Publication of JP2024028453A5 publication Critical patent/JP2024028453A5/ja
Application granted granted Critical
Publication of JP7843302B2 publication Critical patent/JP7843302B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024002413A 2018-02-17 2024-01-11 トリアルキン結合剤及び使用方法 Active JP7843302B2 (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862631683P 2018-02-17 2018-02-17
US62/631,683 2018-02-17
US201862646739P 2018-03-22 2018-03-22
US62/646,739 2018-03-22
US201862663763P 2018-04-27 2018-04-27
US62/663,763 2018-04-27
US201962790300P 2019-01-09 2019-01-09
US62/790,300 2019-01-09
PCT/US2019/018232 WO2019161213A1 (en) 2018-02-17 2019-02-15 Trialkyne linking agents and methods of use
JP2020543533A JP7420727B2 (ja) 2018-02-17 2019-02-15 トリアルキン結合剤及び使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020543533A Division JP7420727B2 (ja) 2018-02-17 2019-02-15 トリアルキン結合剤及び使用方法

Publications (3)

Publication Number Publication Date
JP2024028453A JP2024028453A (ja) 2024-03-04
JP2024028453A5 true JP2024028453A5 (https=) 2024-10-21
JP7843302B2 JP7843302B2 (ja) 2026-04-09

Family

ID=67620056

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543533A Active JP7420727B2 (ja) 2018-02-17 2019-02-15 トリアルキン結合剤及び使用方法
JP2024002413A Active JP7843302B2 (ja) 2018-02-17 2024-01-11 トリアルキン結合剤及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020543533A Active JP7420727B2 (ja) 2018-02-17 2019-02-15 トリアルキン結合剤及び使用方法

Country Status (8)

Country Link
US (1) US20250092072A1 (https=)
EP (1) EP3752166A4 (https=)
JP (2) JP7420727B2 (https=)
CN (2) CN120247964A (https=)
AU (2) AU2019220739B2 (https=)
CA (1) CA3089276A1 (https=)
IL (1) IL276687B2 (https=)
WO (1) WO2019161213A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2019000308A1 (en) * 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
WO2019210308A1 (en) 2018-04-27 2019-10-31 Arrowhead Pharmaceuticals, Inc. Integrin targeting ligands and uses thereof
SG11202105577TA (en) 2019-01-09 2021-06-29 Arrowhead Pharmaceuticals Inc Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
KR20220024153A (ko) 2019-05-24 2022-03-03 엠피리코 인크. 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료
EP4025252A4 (en) * 2019-09-03 2023-10-18 Arcturus Therapeutics, Inc. ASIALOGLYCOPROTEIN RECEPTOR-MEDIATED ADMINISTRATION OF THERAPEUTICALLY ACTIVE CONJUGATES
AU2021340710A1 (en) * 2020-09-11 2023-04-06 Arrowhead Pharmaceuticals, Inc. Skeletal muscle delivery platforms and methods of use
IL301187A (en) * 2020-09-11 2023-05-01 Arrowhead Pharmaceuticals Inc RNAi agents for suppressing DUX4 expression, preparations containing them and uses thereof
CN116323633A (zh) * 2020-09-11 2023-06-23 箭头药业股份有限公司 骨骼肌递送平台及使用方法
US12486502B2 (en) 2021-04-08 2025-12-02 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
CN117858949A (zh) 2021-05-28 2024-04-09 箭头药业股份有限公司 用于抑制粘蛋白5AC(MUC5AC)的表达的RNAi试剂、其组合物及其使用方法
CN113956206B (zh) * 2021-10-25 2023-04-28 深圳湾实验室坪山生物医药研发转化中心 一种用于修饰蛋白质赖氨酸残基的探针及其制备方法
US20250197859A1 (en) * 2022-03-28 2025-06-19 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
KR20240163743A (ko) * 2022-03-28 2024-11-19 엠피리코 인크. 변형된 올리고뉴클레오티드
EP4540390A2 (en) 2022-06-15 2025-04-23 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use
CN120731091A (zh) * 2022-12-14 2025-09-30 阿尔尼拉姆医药品有限公司 用于肝外递送的α-Vβ-6(αvβ6)整合素配体
AU2024302964A1 (en) 2023-06-13 2025-12-18 Tuojie Biotech (Shanghai) Co., Ltd. Sirna targeting mmp7, sirna conjugate and medical use thereof
CN121586578A (zh) 2023-08-24 2026-02-27 上海拓界生物医药科技有限公司 靶向RAGE的RNAi剂及其医药用途
CN121843941A (zh) 2023-09-27 2026-04-10 上海拓界生物医药科技有限公司 含三氮唑基化合物、制备方法及用途
WO2025137390A1 (en) 2023-12-20 2025-06-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of activin receptor-like kinase 7 (alk7), compositions thereof, and methods of use
CN120309684A (zh) * 2024-01-15 2025-07-15 武汉人福创新药物研发中心有限公司 靶向化合物及其用途
US12551569B2 (en) 2024-03-31 2026-02-17 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use
US20260021195A1 (en) 2024-06-20 2026-01-22 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2021351A2 (en) 2006-04-28 2009-02-11 Centre National de la Recherche Scientifique Method for the synthesis of triazole-containing oligonucleotide derivatives
GB201313201D0 (en) * 2013-07-24 2013-09-04 Univ East Anglia Virus Detection
JP6584412B2 (ja) 2014-01-15 2019-10-02 ベースクリック ゲーエムベーハー 糖修飾核酸分子
JP6987641B2 (ja) * 2015-05-12 2022-01-05 ブリンクバイオ インコーポレイテッド シリコン系薬物複合体及びその使用方法
WO2018013525A1 (en) * 2016-07-11 2018-01-18 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
TN2019000308A1 (en) * 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP2024028453A5 (https=)
JP2021502120A5 (https=)
JP2021517113A5 (https=)
JP2023171659A5 (https=)
JP2023113843A5 (https=)
JPWO2019092283A5 (https=)
JP2023107988A5 (https=)
JP2023166381A5 (https=)
JPWO2019161213A5 (https=)
JP2021533800A5 (https=)
JP2021517126A5 (https=)
JPWO2022158528A5 (https=)
JPWO2023106310A5 (https=)
RU2220140C2 (ru) Производное циклических амидов, фармацевтическая композиция и лекарственное средство, его содержащее, и способ лечения аллергического заболевания
JP2009504862A5 (https=)
JP2023101503A5 (https=)
JP2007538042A5 (https=)
JPWO2020231776A5 (https=)
JPWO2020158687A5 (https=)
JPWO2022047583A5 (https=)
JPWO2023129956A5 (https=)
JP2021095514A5 (https=)
JPH1060297A5 (https=)
JP2005538151A5 (https=)
JPWO2022150911A5 (https=)